Don't Need Much Money is exactly what it sounds like: a site about needing less, so you have more. More time. More freedom. More room to actually live. The idea is simple. The less money you need to survive, the more time you have to thrive. Lower your living costs, live a healthy lifestyle focused on longevity and mobility, stay out of debt, and build a little savings, and you buy yourself something far more valuable than money: time. Time to do what you actually love, spend with people you care about, and put toward things that matter. This site is my own real life running that experiment. Most of what you'll find here are recipes and day-to-day habits. They aren't filler posts, it's intentional. Cooking from scratch, buying smart, wasting less, eating well, and staying healhty, fit, and limber all without spending much are some of the most direct ways I practice this philosophy day to day. This blog doubles as my own recipe box and exercise notes, and I share it b...
Those who follow this blog know that one of my issues with economic opportunity is the current interpretation of anti-trust law. It is a narrow definition that only looks at if the consumer is harmed. If there is not a risk of prices increasing or quality of products or services diminishing, then a company can keep acquiring competitors, eliminating jobs, and squash startup competitors.
Well, we may have a new sheriff in town, 32-year old Lina Khan. She was appointed this week as commission of the Federal Trade Commission (FTC) who is responsible for interpreting and executing anti-trust law. She has been vocal about her position against tech company monopolies. Perhaps she will lead the charge in breaking up big tech and creating more level playing fields to tap into the monopolistic networks these companies own and control.
This will certainly be a key focus for her. One other area I would like for her to focus on is the pharmaceutical industry. There are terrible pricing issues that have gone unchecked for far too long. An example of one of the practices is when drug companies pay off generic drug manufacturers to delay them from making generic versions of drugs coming off patent. This should not happen and needs to be stopped.
I am hopeful that this may be a changing of the tide. If it is, it will be interesting to watch what it does to the stock prices of some of these targeted monopolistic companies. Will they go down or could they increase with the market valuing the parts more than the sum? And will some of them voluntarily change their behavior at the expense of profits/stock price to build goodwill with customers and legislators?
Comments
Post a Comment